^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Penile Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pembrolizumab is preferred in the second-line setting for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) penile cancer…
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Small Intestinal Carcinoma)
    New
    Title:

    European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

    Excerpt:
    Merck...announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with...unresectable or metastatic gastric, small intestine or biliary cancer, who have disease progression on or following at least one prior therapy.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Invest New Drugs
    Title:

    Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial

    Published date:
    03/26/2021
    Excerpt:
    One patient with a microsatellite instability high (MSI-H) tumor experienced a durable partial response to pembrolizumab, underwent surgical consolidation…
    DOI:
    10.1007/s10637-021-01100-x
    Trial ID:
    NCT02721732